Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.
To investigate blockchain processes and make distribution information retrieval more efficient, the FDA tapped big name companies for a supply chain security pilot program.
Merck & Co intends to close ten more manufacturing plants to further shrink its footprint as it continues to restructure after its 2009 megamerger with Schering-Plough.
Merck & Co plans to cut 7,200 jobs, joining the growing list of big pharma firms enacting restructuring measures in the face of falling earnings and an uncertain market future.
The US Food and Drug Administration (FDA) has sent Merck & Co a
warning letter saying it has failed to correct a number of
manufacturing deficiencies at its main vaccine manufacturing plant
in West Point, Pennsylvania.
Merck Serono intends to forge ahead with severing its investment in
diabetes and either sell or partner out its existing research and
development (R&D) activities in this field, which it no longer
feels able to compete in effectively.
A new 3D model of the human liver that even has its own blood
supply could pump new life into drug safety tests by predicting
problems earlier and cut down on animal experiments.
GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD) have made
further moves in their plans to boost their presence in Singapore,
a region growing in popularity for biopharmaceutical research and
manufacture.
Drug giant Merck & Co has seen flat sales and a rise in
operating costs in the first quarter of 2006, as its restructuring
initiative, which contract manufacturers welcomed, takes its toll
on the company.
Merck & Co said it would cut an additional $1 billion (€832
million) through 2010 as it struggles to regain R&D momentum
after mounting lawsuits, generic competition and falling revenue
and profit threaten to engulf the company,...
Merck is to cut 7,000 jobs, close five factories and three research
facilities, as the US pharmaceutical company continues to suffer
from the devastating repercussions caused by its painkiller Vioxx
and the pending lawsuits.
In-PharmaTechnologist.com reports its periodic round-up of new
appointments in the pharmaceutical sector, headlined this week by
the appointment of a new head of manufacturing at US drugmaker
Merck & Co.
The sudden departure of Merck & Co's chairman and chief
executive, Raymond Gilmartin, last week brings into sharp
perspective the difficulties facing the ailing US drugmaker,
reports Phil Taylor.
Merck & Co, still reeling from the impact of pulling its
painkiller Vioxx (rofecoxib) from the market, is to slash its staff
by 5,100 positions in a bid to save hundreds of millions of dollars
by the end of the year.
Merck & Co continued a run of bad luck in its product
development portfolio yesterday with the news that it had
terminated the development of a drug to treat diabetes.
